Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 7 April 2026Expected publication date: 18 June 2026